E
Epocrates
Reference information about drugs and diseases, and diagnostic tools for healthcare professionals
About Epocrates
Epocrates operates in the healthcare technology market, providing a comprehensive medical reference app primarily for healthcare providers. The app offers a wide range of features including drug information, interaction checks, pill identification, clinical practice guidelines, and formulary data. It serves a diverse client base of over one million healthcare professionals, including physicians, pharmacists, and nurses. The business model is subscription-based, with users paying either an annual fee of $174.99 or a monthly fee of $16.99 to access premium content such as robust disease and alternative medicine information, labs, and diagnostic data. Epocrates generates revenue through these subscriptions, offering essential clinical decision support that saves time and enhances the quality of care. The company’s content is curated by a dedicated team of pharmacists, physicians, and associates to ensure it is objective, accurate, current, concise, and clinically relevant.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Watertown, United States
- Open positions
- None listed
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Clinical Decision Support, Biotech and Pharma, Physician Support Tools, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2010
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Epocrates.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2013 | $0 | — | athenahealth | — |
| IPO✓Exit | Feb 2011 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Epocrates is 450K monthly website visits, up 15.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
- BCBay City Capital
InterWest Partners
Sprout Group
Three Arch Partners
Other known investors5 additional known investors
athenahealth
Industry Ventures
Millennium Technology Value Partners- MTMillennium TVP
New Leaf Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Epocrates on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epocrates’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.